Bispecific antibodies as novel bioconjugates

被引:55
|
作者
Cao, Y [1 ]
Suresh, MR [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
关键词
D O I
10.1021/bc980044l
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Bispecific antibodies are unique macromolecular heterobifunctional cross-linkers with two different binding specificities within a single molecule. As ideal bioconjugates, they can specifically glue any two different molecules together without the need for chemical conjugation. With this unique feature, they have immense potential in biological and immunological fields. Their applications range from immunohistochemistry, immunoassays, ra, radioimmunotherapy, and immunotherapy. Recently, a new second generation of bispecific molecules, bispecific single chain Fv and diabodies, has been produced by DNA recombinant technology. They can be considered as the ultimate magic bullets for in vivo applications. They may theoretically improve tumor or pathogen targeting and minimize side effects, eventually replacing the full-length bispecific antibodies. Emphasizing on developmental methodology and clinical applications of bispecific antibodies, this review gives a bird's-eye view of these unique bioconjugates.
引用
收藏
页码:635 / 644
页数:10
相关论文
共 50 条
  • [1] Monoclonal and bispecific antibodies as novel therapeutics
    Booy, EP
    Johar, D
    Maddika, S
    Pirzada, H
    Sahib, MM
    Gehrke, I
    Loewen, S
    Louis, SF
    Kadkhoda, K
    Mowat, M
    Los, M
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2006, 54 (02) : 85 - 101
  • [2] Monoclonal and bispecific antibodies as novel therapeutics
    Evan P. Booy
    Dina Johar
    Srilekha Maddika
    Hasan Pirzada
    Mickey M. Sahib
    Iris Gehrke
    Shauna Loewen
    Sherif F. Louis
    Kamran Kadkhoda
    Michael Mowat
    Marek Los
    Archivum Immunologiae et Therapiae Experimentalis, 2006, 54 : 85 - 101
  • [3] Design and production of novel tetravalent bispecific antibodies
    M. Josefina Coloma
    Sherie L. Morrison
    Nature Biotechnology, 1997, 15 : 159 - 163
  • [4] Design and production of novel tetravalent bispecific antibodies
    Coloma, MJ
    Morrison, SL
    NATURE BIOTECHNOLOGY, 1997, 15 (02) : 159 - 163
  • [5] Development of novel bispecific immune modulating antibodies
    Vitale, Laura A.
    Thomas, Lawrence J.
    He, Li-Zhen
    O'Neill, Thomas
    Widger, Jenifer
    Crocker, Andrea
    Testa, James
    Sundarapandiyan, Karuna
    Forsberg, Eric
    Boyer, James
    Storey, James
    Goldstein, Joel
    Marsh, Henry C.
    Keler, Tibor
    CANCER RESEARCH, 2018, 78 (13)
  • [6] WHICH WILL BE THE BEST PLACE FOR BISPECIFIC ANTIBODIES IN NOVEL THERAPIES
    Einsele, H.
    HAEMATOLOGICA, 2018, 103 : 8 - 8
  • [7] Novel BCMA Targeted ADCs, Bispecific and Trispecific Antibodies
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S161 - S161
  • [8] Bispecific antibodies: a novel approach for targeting prominent biomarkers
    Gupta, Akshita
    Kumar, Yatender
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (11) : 2831 - 2839
  • [9] Bispecific antibodies:: Molecules that enable novel therapeutic strategies
    Fischer, Nicolas
    Leger, Olivier
    PATHOBIOLOGY, 2007, 74 (01) : 3 - 14
  • [10] Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
    Liguori, Luigi
    Polcaro, Giovanna
    Nigro, Annunziata
    Conti, Valeria
    Sellitto, Carmine
    Perri, Francesco
    Ottaiano, Alessandro
    Cascella, Marco
    Zeppa, Pio
    Caputo, Alessandro
    Pepe, Stefano
    Sabbatino, Francesco
    PHARMACEUTICS, 2022, 14 (11)